netFormulary
 Report : Medicines with links to NICE 24/06/2018 16:03:28

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03 Formulary NICE TA146 Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 11.04.02 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir 05.03.03.01 Non Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Non Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 346 Aflibercept for treating diabetic macular oedema
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 486: Aflibercept for treating choroidal neovascularisation
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alirocumab 02.12 Non Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Formulary NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Asfotase alfa 09.08.01 Formulary NICE HST6 Asfotase alfa for treating paediatric-onset hypophosphatasia
Ataluren 10.02.01 Formulary NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA99: Immunosuppressives in renal transplant (Children)
Basiliximab 08.02.02 Formulary NICE TA85: Immunosuppressives in renal transplant (Adults)
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA 260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA446 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capsaicin 10.03.02 Formulary NICE CG177 - Osteoarthritis: care and management
Carfilzomib 08.01.05 Formulary NICE TA457 Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Formulary NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
Cetuximab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
Ciclosporin 11.08.02.04 Non Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Ciclosporin 0.1% (1mg/1ml) Eye Drops 11.04.02 Formulary TA 369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate 05.01.07 Formulary TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Formulary NICE TA441 Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA 418: Dapagliflozin in triple therapy for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Non Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 13.05.03 Formulary NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Docetaxel 08.01.05 Formulary NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197 (Atrial fibrillation - dronedarone)
Eculizumab 09.01.03 Formulary NICE HST 1 - Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir & grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eliglustat 09.08.01 Formulary NICE HST5 Eliglustat for treating type 1 Gaucher disease
Elosulfase alfa 09.08.01 Formulary NICE HST 2 - Elosulfase alfa for treating mucopolysaccharidosis type IVa
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.04.02 Formulary NICE TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Non Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Non Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etelcalcetide 09.05.01.02 Formulary NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (Superceded by NICE TA432)
Everolimus 08.01.05 Formulary NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Evolocumab 02.12 Non Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 06.01.02.03 Formulary NICE TA248: Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
Exenatide prolonged release 06.01.02.03 Non Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 5mg tablets 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fluocinolone 190 microgram intravitreal implant 11.04.01 Formulary NICE TA301Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fondaparinux 02.08.01 Formulary Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine 08.01.03 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Glatiramer Acetate 08.02.04 Formulary NICE CG32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
Glecaprevir & Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Ibandronic Acid 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Insulin Glargine biosimilar Abasaglar® 06.01.01.02 Formulary NG17: Type 1 diabetes in adults: diagnosis and management
Interferon Beta 08.02.04 Formulary NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ivabradine 02.06.03 Formulary Ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ixekizumab 13.05.03 Formulary NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Liraglutide 06.01.02.03 Formulary NICE NG28 - Type 2 diabetes in adults: management
Liraglutide 06.01.02.03 Formulary NICE TA203: Liraglutide for the treatment of type 2 diabetes mellitus (Replaced by NICE NG28)
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Mannitol inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mepolizumab 03.04.02 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Mifamurtide 08.02.04 Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Migalastat 09.08.01 Formulary Highly specialised technologies guidance HST4: Migalastat for treating Fabry disease
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Mycophenolate Mofetil 08.02.01 Formulary NICE TA85: Immunosuppressive therapy for renal transplantation in adults
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 50 mg tablets 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Formulary NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nintedanib 03.11 Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Formulary NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Obeticholic acid 01.09.01 Formulary NICE TA443 Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Ocriplasmin 11.08.02 Formulary NICE TA 297 Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 50mg capsules 08.01.05 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA465 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir & paritaprevir & ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oxaliplatin 08.01.05 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.03.04.01 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 3750iu vial 08.01 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Perampanel 04.08.01 Non Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus cream 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Formulary NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Formulary NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 274 Ranibizumab for treating diabetic macular oedema
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Regorafenib 08.01.05 Formulary NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab 03.04.02 Formulary NICE TA479 Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risedronate 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Roflumilast 03.03.03 Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial)
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril & valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary NICE TA350: Plaque Psoriasis
Simeprevir 05.03.03.02 Non Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir & Ledipasvir 05.03.03.02 Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Sofosbuvir & velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir, Velpatasvir & Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin - adults 06.05.01 Formulary NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
Somatropin (children) 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Sorafenib 08.01.05 Formulary NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Formulary NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Tacrolimus ointment 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir Disproxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tinzaparin 02.08.01 Formulary Venous thromboembolism: reducing the risk for patients in hospital
Tinzaparin 02.08.01 Formulary Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
Tobramycin 05.01.04 Formulary TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Formulary NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine and tipiracil 08.01.03 Formulary NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
upoNilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
upoNilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
upoNilotinib 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
upoNilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab (Updated March 2017)
Ustekinumab 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis (Updated March 2017)
Ustekinumab 01.05.03 Formulary NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Vemurafenib 08.01.05 Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Verteporfin 15mg Injection 11.08.02 Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vitamin B & C injection 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Vitamin B & C injection 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Vortioxetine 04.03.03 Non Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Vortioxetine 04.03.04 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zanamivir inhalation 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zanamivir inhalation 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zoledronic Acid 5mg injection 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Non Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
North of Tyne and Gateshead Area Prescribing Committee